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1 10% • • •
2 10% • •
3 5% • • • • •
4 10% • • • • • • •
5 5% • • • • • • • •
6 5% • • • • • • • •
7a 18.1% • • • •
7b 9.5% •
Fig 1. HyClone Cell Boost supplements for development of high-performing perfusion media. 
ADCF = animal-derived component-free.
Fig 3. DoE 2 optimization of pre-selected Cell Boost supplements in small-scale semi-
continuous perfusion models (Step 2). Regression analysis was performed to define the 
final perfusion media.
Fig 5. Optimized perfusion media applied to different bioreactor runs (Step 4). CDM4NS0- or ActiPro-based perfusion media were applied to 500 mL ReadyToProcess WAVE 25 or 50 L XDR 50 
bioreactor perfusion runs. VCD = viable cell density; vvd = media volume per bioreactor volume per day.
Fig 6. Consistent product qualities between basal and Cell Boost-spiked perfusion media. Quality attributes were 
analyzed for N-glycosylation, charge distribution, and aggregation/fragmentation. 
Fig 7. Comparison of small-scale versus bioreactor perfusion cultures. 
Small-scale perfusion cultures daily bled at 30% was predictive for many 
parameters of a ReadyToProcess WAVE bioreactor perfusion run.
Fig 4. Effect of daily cell bleed (Step 3).  
Semi-perfusion cultures were bled daily at 
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0 2 6 8 10 12
BR1 - Determinaon of CSPRmin
by constant vvd
BR2 - Biomass producon by
constant low CSPR (< 30 pL/c/d)
BR3 - 500 mL steady-state perfusion
at CSPR 20 pL/c/d
BR4 - 50 L steady-state perfusion
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ReadyToProcess WAVE 25 Perfusion
Xcellerex XDR 50
ActiPro + Cell Boost 1 + Cell Boost 3
M5No A1 A2 A2G1 FA1 FA2 FA2G1 FA2G2
M5No A1 A2 A2G1 FA1 FA2 FA2G1 FA2G2



















































































Perfusion start in CDM4NS0
10 days in CDM4NS0 + Gluc
10 days in CDM4NS0 + Cell Boost 1 + Cell Boost 3
17 days in CDM4NS0 + Cell Boost 1 + Cell Boost 3 
Start CDM4NS0 + Gluc
10 days in CDM4NS0 + Gluc
Start CDM4NS0 + Cell Boost 1 + Cell Boost 3












Cell Boost optimization (DoE 2)
Step 2






ReadyToProcess WAVE 25 Xcellerex XDR 50
+ Fresh
media
Fig 2. Fast workflow for perfusion media 
development. After initial definition of optimal 
basal media, eight different Cell Boost 
supplements were screened, optimized, and 
tested in four consecutive steps using DoE and 
small-scale semi-continuous perfusion models.






Perfusion mode Semi-perfusion VCD const –
Vessel Tube ReadyToProcess WAVE 25 –
Basal media CDM4NS0 CDM4NS0 –
Supplement Cell Boost 1 + Cell Boost 3 Cell Boost 1 + Cell Boost 3 –
Period Days 8 to 15 Days 6 to 11 –
pH control None Setpoint pH 6.8 –
Perfusion rate (vvd) 1.0 0.9 1.15
Harvest rate (vvd) 0.7 0.5 1.32
Bleed rate (vvd) 0.3 0.3 0.90
Total cell conc. (mio. cell/mL) 40 43 0.93
Viability (%) 98 96 1.02
Titer (mg/L) 1034 1123 0.92
µv (1/d) 0.36 0.48 0.76
qP (pg/cell/d) 27.8 24.9 1.12
CSPR (pL/cell/d) 21.1 21.9 0.96
Glucose (mg/L) 7284 5884 1.24
Lactate (mg/L) 2137 1580 1.35
Glutamate (mg/L) 267 107 2.49
Glutamine (mg/L) 52 0 N/A
NH4+ (mg/L) 84 28 3.02
qGlucose cons. (pg/cell/d) 221 224 0.99
qLactate prod. (pg/cell/d) 51 31 1.65
qGlutamate cons. (pg/cell/d) 9.4 12.0 0.78
qGlutamine prod. (pg/cell/d) 0.5 -0.3 -1.58
qNH4+ prod. (pg/cell/d) 0.6 0.2 2.79
qLactate/qGlucose (mol/mol) 0.4 0.3 1.41
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Process time (days)






















2 +1 -1 -1 -1
3 -1 +1 -1 -1
4 +1 -1 +1 -1
5 -1 +1 +1 -1
6 +1 +1 +1 -1
7 -1 -1 -1 +1
8 -1 +1 -1 +1
9 +1 +1 -1 +1
10 -1 -1 +1 +1
11 +1 -1 +1 +1
12 +1 +1 +1 +1













d)14 +1 0 0 0
15 0 -1 0 0
16 0 +1 0 0
17 0 0 -1 0
18 0 0 +1 0
19 0 0 0 -1
20 0 0 0 +1








22 0 0 0 0
23 0 0 0 0
Regression analysis
Two novel perfusion media















CDM4NS0 + Gluc 0% bleed
CDM4NS0 + Cell Bost 1 + Cell Bost 3 0% bleed
CDM4NS0 + Cell Bost 1 + Cell Bost 3 20% bleed
CDM4NS0 + Cell Bost 1 + Cell Bost 3 30% bleed
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CDM4NS0 + Gluc 0% bleed
CDM4NS0 + Cell Bost 1 + Cell Bost 3 0% bleed
CDM4NS0 + Cell Bost 1 + Cell Bost 3 20% bleed
CDM4NS0 + Cell Bost 1 + Cell Bost 3 30% bleed
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A generally applicable perfusion medium development workflow 
was applied to two different HyClone CHO basal media: ActiPro and 
CDM4NS0. In a first screening round (Fig 2, step 1) beneficial effects 
of Cell Boost supplements 1, 3, 7a, and 7b were identified using a DoE 
approach in spiked batch cultures. The pre-selected supplements 
were subsequently applied to a second DoE using 10 mL shaking 
cultures in a semi-continuous perfusion mode by daily media exchange 
(Fig 2, step 2), where the primary objective was to fine-tune the ratio 
of pre-selected Cell Boost supplements. High VCDs of more than 
50 × 106 cells/mL in a quasi steady-state were reached. Spiking basal 
medium with Cell Boost supplements improved viabilities and daily 
titers, with values up to 1 g/L. Subsequent bleeding experiments in 
semi-perfusion cultures (Fig 2, step 3) revealed higher maintained 
growth rates at higher bleeding rates, correlating with higher specific 
productivities. Despite lower steady-state VCDs, increased specific 
productivity resulted in the titer increasing by 20% when a 30% daily 
bleed was used. N-glycosylation profiles of antibodies produced in the 
Abstract
Cell culture perfusion processes are considered optimal for a truly 
integrated continuous biomanufacturing pipeline. The nutrient-rich 
but balanced media should be designed to support very low cell-
specific perfusion rates (CSPR) that minimize media consumption 
while maximizing viable cell days and productivities. Optimized 
processes at low CSPR drastically reduce equipment costs, lab 
space, and product dilution. Finally, operating at very low CSPR will 
allow for mammalian cell bioprocesses to run as true chemostat 
cultures in the future. 
In this study, we demonstrate a general workflow to develop high-
performing perfusion media using small-scale models and transfer 
the process to a 50 L scale at CSPR of 20 pL/cell/d. 
Conclusion
• A DoE-based workflow was developed to leverage established 
feed supplements for definition of novel, high-performing 
perfusion media.
• Small-scale models in semi-continuous perfusion mode were used 
to screen different conditions within a single operator.
Materials and methods
Cell line: HyClone™ Chinese hamster ovary (CHO) cells (CHO-K1, IgG1)
Basal media: HyClone CDM4NS0 or Hyclone ActiPro™
Feed supplements: see Figure 1
Analytical methods: Vi-CELL™ (viable cell density [VCD]),  
BioProfile™ 100 plus (glucose, lactate, glutamine, glutamate, NH4+), 
Osmomat 030 (mOsm/kg), Octet™ QK (titer)
Design of Experiment (DoE, Steps 1 and 2)
Three DoE levels (-1, 0, +1) 
• Level -1: translates into 0% spike concentration
• Level 0: half-maximum spike concentrations
• Level +1: all Cell Boost™ supplements were mixed according to 
total amino acid concentration and spiked into basal media to 
reach 400 mOsm/kg; design of DoE matrix and establishment of 
final statistical models were performed using MODDE™ software
Semi-continuous small-scale perfusion models (Steps 2 and 3)
Start VCD: 10 × 106 cells/mL in 10 mL (spiked) basal medium 
One volume exchange per day (1 reactor volume [RV]/d) by 
centrifugation at 300 g/7 min after bleeding if applicable
220 rpm at 50 mm shaking diameter in a Kuhner shaker instrument 
at 7% CO2 and 85% humidity at 37°C
Bioreactor verification runs (Step 4)
Optimized CDM4NS0 or ActiPro perfusion medium was applied 
to perfusion bioreactors using a ReadyToProcess WAVE™ 25 or 
Xcellerex™ XDR 50 bioreactor; cells seeded at 1 × 106 cells/mL in 
unspiked basal medium, and perfusion initiated on days 2 to 4 at a 
working volume of 500 mL or 40 L; culture parameters set to control 
> 30% dissolved oxygen (DO), 37°C, pH 6.8 to 7.0
semi-continuous models showed a decreased galactosylation patterns 
at later process times.
Two novel perfusion media developed within this project and based on 
basal CDM4NS0 or ActiPro and Cell Boost 1 and Cell Boost 3 were applied 
to different bioreactor perfusion verification runs. Using a continuous 
volumetric perfusion rate, the minimum CSPR of 10 pL/cell/d was 
determined to generate the highest VCD of more than 200 × 106 cells/mL.  
A similar high VCD was reached with ActiPro + Cell Boost 1/3 by using 
a constant CSPR of 15 to 30 pL/cell/d to reduce medium consumption. 
The novel perfusion media were also applied to bioreactor production 
runs at a constant VCD of 50 × 106 cells/mL at a 500 mL or 40 L scale.  
An increase of galactosylated glycan species was observed over 
process time, and a good correlation of various bioreactor parameters 
compared to the 30%-bled small-scale model was identified. Major 
differences were only found for the glutamate/glutamine/NH4+ behavior, 
which might be responsible for the discrepancy of the terminal 
galactosylation profile.
• A minimum CSPR of 10 pL/cell/d was determined by constant 
volumetric perfusion rates in a ReadyToProcess WAVE 25 
bioreactor to reach 200 × 106 cells/mL.
• A steady-state production perfusion run was scaled up to an 
Xcellerex XDR 50 L bioreactor.
• Glycoslyation increased in galactoslyated species in bioreactor 
perfusion runs but decreased in the semi-continuous models, likely 
due to higher amounts of ammonia accumulation.
• Critical culture parameters were very similar between bled small-
scale cultures and the perfusion bioreactor at similar CSPRs.
